U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ® [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration (FDA) approval in November 2023 IXCHIQ ® is the first and only vaccine approved to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to the chikungunya virus Saint-Herblain (France), February 29, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend use of Valneva's single-dose chikungunya vaccine IXCHIQ ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP recommends IXCHIQ ® for persons aged =18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered for persons traveling to a country or territory without an outbreak but with evidence of CHIKV transmission within
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateGlobeNewswire
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]Yahoo! Finance
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FGlobeNewswire
- Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
VALN
Sec Filings
- 3/26/24 - Form 6-K
- 3/22/24 - Form 20-F
- 3/22/24 - Form 6-K
- VALN's page on the SEC website